Zynerba Pharmaceuticals, Inc. (0M40.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Zynerba Pharmaceuticals, Inc.
Address
80 West Lancaster Avenue
Devon, PA 19333
United States of America (the)
Phone
484 581 7505
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
25
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| James E. Fickenscher | Chief Financial Officer & Vice President of Corporation Devel. (Leave of Absence) | 607,622 | 1964 |
| Kenneth T. Jones | Vice President, Corporation Controller & Interim Chief Financial Officer | 0 | 1964 |
Description
Zynerba Pharmaceuticals, Inc. functions as a specialized pharmaceutical entity currently undergoing clinical development. Its primary endeavor is the creation of medicinal cannabinoid treatments, applied transdermally, intended for rare and uncommon neuropsychiatric conditions. Among its key initiatives is the development of Zygel, a pharmaceutical-grade cannabidiol precisely engineered as a gel for enhanced transdermal permeation. Previously known as AllTranz, Inc., the corporation formally adopted the name Zynerba Pharmaceuticals, Inc. in August 2014. Established in 2007, its corporate headquarters are located in Devon, Pennsylvania.
